Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Atreya Dash

Showing results (71-80 of 83) with videos related to

Pageof 9
Sort By:
The Journal of Urology|October 26, 2019
African American Race is Not Associated with Risk of Reclassification during Active Surveillance: Results from the Canary Prostate Cancer Active Surveillance StudyJeannette M Schenk, Lisa F Newcomb, Yingye Zheng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 5, 2020
17-Gene Genomic Prostate Score Test Results in the Canary Prostate Active Surveillance Study (PASS) CohortDaniel W Lin, Yingye Zheng, Jesse K McKenney, et al.
The Journal of Urology|April 30, 2025
Magnetic Resonance Imaging at Second Surveillance Biopsy After Diagnosis in Patients With Grade Group 1 Prostate Cancer in the Canary Prostate Active Surveillance StudyMeera R Chappidi, Lisa F Newcomb, Yingye Zheng, et al.
Cancer|September 13, 2021
Treatment in the absence of disease reclassification among men on active surveillance for prostate cancerPeter S Kirk, Kehao Zhu, Yingye Zheng, et al.
The Journal of Urology|July 13, 2022
Impact of Prostate Health Index Results for Prediction of Biopsy Grade Reclassification During Active SurveillanceChristopher P Filson, Kehao Zhu, Yijian Huang, et al.
Journal of the National Cancer Institute|August 12, 2025
Prostate Cancer Imaging Stewardship: a multi-modal, physician-centered intervention for guideline-concordant imagingDanil V Makarov, Jerry K Thomas, Shannon Ciprut, et al.
The Journal of Urology|April 10, 2020
Health Related Quality of Life of Patients with Bladder Cancer in the RAZOR Trial: A Multi-Institutional Randomized Trial Comparing Robot versus Open Radical CystectomyMaria F Becerra, Vivek Venkatramani, Isildinha M Reis, et al.
JAMA|May 30, 2024
Long-Term Outcomes in Patients Using Protocol-Directed Active Surveillance for Prostate CancerLisa F Newcomb, Jeannette M Schenk, Yingye Zheng, et al.
Cancer Medicine|April 25, 2022
Germline mutations in penetrant cancer predisposition genes are rare in men with prostate cancer selecting active surveillanceLauren Brady, Lisa F Newcomb, Kehao Zhu, et al.
European Urology|August 5, 2025
Neoadjuvant Pembrolizumab and Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Nonurothelial Histologic Subtypes of Muscle-invasive Bladder Cancer: A Phase 2 TrialRuben Raychaudhuri, Ali Raza Khaki, Mary W Redman, et al.
Pageof 9

Showing results (71-80 of 83) with videos related to

Sort By:
Pageof 9
The Journal of Urology|October 26, 2019
African American Race is Not Associated with Risk of Reclassification during Active Surveillance: Results from the Canary Prostate Cancer Active Surveillance StudyJeannette M Schenk, Lisa F Newcomb, Yingye Zheng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 5, 2020
17-Gene Genomic Prostate Score Test Results in the Canary Prostate Active Surveillance Study (PASS) CohortDaniel W Lin, Yingye Zheng, Jesse K McKenney, et al.
The Journal of Urology|April 30, 2025
Magnetic Resonance Imaging at Second Surveillance Biopsy After Diagnosis in Patients With Grade Group 1 Prostate Cancer in the Canary Prostate Active Surveillance StudyMeera R Chappidi, Lisa F Newcomb, Yingye Zheng, et al.
Cancer|September 13, 2021
Treatment in the absence of disease reclassification among men on active surveillance for prostate cancerPeter S Kirk, Kehao Zhu, Yingye Zheng, et al.
The Journal of Urology|July 13, 2022
Impact of Prostate Health Index Results for Prediction of Biopsy Grade Reclassification During Active SurveillanceChristopher P Filson, Kehao Zhu, Yijian Huang, et al.
Journal of the National Cancer Institute|August 12, 2025
Prostate Cancer Imaging Stewardship: a multi-modal, physician-centered intervention for guideline-concordant imagingDanil V Makarov, Jerry K Thomas, Shannon Ciprut, et al.
The Journal of Urology|April 10, 2020
Health Related Quality of Life of Patients with Bladder Cancer in the RAZOR Trial: A Multi-Institutional Randomized Trial Comparing Robot versus Open Radical CystectomyMaria F Becerra, Vivek Venkatramani, Isildinha M Reis, et al.
JAMA|May 30, 2024
Long-Term Outcomes in Patients Using Protocol-Directed Active Surveillance for Prostate CancerLisa F Newcomb, Jeannette M Schenk, Yingye Zheng, et al.
Cancer Medicine|April 25, 2022
Germline mutations in penetrant cancer predisposition genes are rare in men with prostate cancer selecting active surveillanceLauren Brady, Lisa F Newcomb, Kehao Zhu, et al.
European Urology|August 5, 2025
Neoadjuvant Pembrolizumab and Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Nonurothelial Histologic Subtypes of Muscle-invasive Bladder Cancer: A Phase 2 TrialRuben Raychaudhuri, Ali Raza Khaki, Mary W Redman, et al.
Pageof 9